RT - Journal TY - JOUR A1 - Retnaswami, Chandra A1 - Pai, Anupama A1 - Chithra, P A1 - Vidhya Annapoorni, C A1 - Vargese, Jogin T1 - Nondevice-assisted therapy for advanced Parkinson's disease with severe complications revisited for resource-restricted setup YR - 2021/4/1 JF - International Journal of Health & Allied Sciences JO - Int J Health Allied Sci SP - 141 OP - 144 VO - 10 IS - 2 UL - https://www.ijhas.in/article.asp?issn=2278-344X;year=2021;volume=10;issue=2;spage=141;epage=144;aulast=Retnaswami;t=5 DO - 10.4103/ijhas.IJHAS_119_20 N2 - INTRODUCTION: A good percentage of patients with parkinsonism land up with moderate-to-severe complications after 5 years of treatment which causes severe disability to patients and caregivers. Device-assisted treatments do not always give consistent results and availability and affordability is also a problem. Therefore, we, in our charitable hospital, tried in six consecutive patients the role of liquid Levodopa Carbidopa Ascorbic acid Solution therapy which is relatively cheap and does not need technical expertise. MATERIALS AND METHODS: Patients who qualified as primary Parkinsonism and had severe complications as per the UPDR Section IV scoring and were considered unsuitable for device-assisted treatment options for various reasons were included for the study. They were given the LCAS therapy and scores repeated at 7 days and 4–6-month follow-up. RESULTS: All patients had improved in UPDR IV scores, Everyday Abilities Scale for India, Zarit's score, and GDR. One patient had hyponatremia and all others remained stable at 4–6-month follow-up with 75% or less of their previous dose. All the parameters under dyskinesias and three of four parameters under fluctuations showed sustained improvement with significant P value at 1 week and 4–6 months in all cases. CONCLUSION LCAS is an easily accessible, cost effective treatment option which significantly improves quality of life in patients, who are not eligible or cannot afford Deep Brain Stimulation. ER -